Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 18/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 8/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.83 |
| ▸ | CIT | O14578 | 1/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.83 |
| ▸ | HLA-A | P04439 | 1/20 | 0.83 |
| ▸ | RET | P07949 | 1/20 | 0.83 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.83 |
| ▸ | FRK | P42685 | 1/20 | 0.83 |
| ▸ | CDK8 | P49336 | 1/20 | 0.83 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.83 |
| ▸ | STK3 | Q13188 | 1/20 | 0.83 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.83 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.83 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.83 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL19639128 | 1.00 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL1685425 | 1.00 | KDR (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL5154569 | 0.94 | KDR (0.89) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.93 | KDR (0.88) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL18286 | 0.91 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29350047 | 0.91 | FLT1 (1.00) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905616 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29633763 | 0.90 | FLT1 (0.97) | KDRFLT1PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030442-A1 | COMBINATION THERAPIES | CAO ZHU ALEXANDER (US) | 2020-01-30 | — | — | US | claimed |
| EP-3519558-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | Organovo, Inc. (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064323-A1 | USE OF ENGINEERED RENAL TISSUES IN ASSAYS | ORGANOVO, INC. (US) | 2018-04-05 | — | — | WO | claimed |
| US-20170340733-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-11-30 | — | — | US | claimed |
| EP-3233918-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100882-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | claimed |
| US-20100278824-A1 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | FIDLER ISAIAH JOSH | 2010-11-04 | — | — | US | claimed |
| US-20100280035-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER | BECKER DIETER | 2010-11-04 | — | — | US | claimed |
| US-20080219977-A1 | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2008-09-11 | — | — | US | claimed |
| EP-1919459-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER | Novartis AG (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007022944-A1 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | claimed |
| WO-2007014335-A2 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-01 | — | — | WO | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | DRACEN PHARMACEUTICALS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| EP-0970070-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035958-A1 | PHTHALAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | KDR 2036/4885FLT1 2214/4885PDGFRB 2098/4885 |
| US-20200030442-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | KDR 1196/4885FLT1 1395/4885PDGFRB 236/4885 |
| US-20170340733-A1 | COMBINATION THERAPIES | BRCA1, TP53, VHL | KDR 1196/4885FLT1 1395/4885PDGFRB 236/4885 |
| US-20100278824-A1 | COMBINATIONS COMPRISING GEMCITABINE AND TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER | PDGFRA, PDGFRB, TEK | KDR 4/4885FLT1 9/4885PDGFRB 2/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | KDR 16/4885FLT1 4/4885PDGFRB 91/4885 |
| US-20080219977-A1 | Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer | PDGFRA, PDGFRB, TEK | KDR 4/4885FLT1 9/4885PDGFRB 2/4885 |
| US-12637415-B2 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | GLS, GLUL, GLS2 | KDR 1358/4885FLT1 901/4885PDGFRB 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.